Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for acute CRPS type 1 with inflammatory signs
NL-OMON21058Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial in Complex Regional Pain Syndrome Type 1 (CRPS-1) comparing Infliximab with Placebo (2 arms). Primary endpoint: Reduction in clinical signs of regional inflammation. Started Nov 2005; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
Complex Regional Pain Syndrome Type 1 (CRPS-1)
Beyond the preview
Go deeper on NL-OMON21058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21058.